Video Experimental Relacionado

Updated: Jun 12, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Pipeline mundial de desarrollo de fármacos para la tuberculosis: la necesidad y la realidad

Zhenkun Ma¹, Christian Lienhardt, Helen McIlleron

¹Global Alliance for TB Drug Development, New York, NY 10005, USA. zhenkun.ma@tballiance.org

Lancet (London, England)

|May 22, 2010

Resumen

El suministro mundial de medicamentos para la tuberculosis (TB) sigue siendo insuficiente a pesar del progreso reciente. El aumento de los esfuerzos y la financiación son cruciales para desarrollar nuevos tratamientos contra la tuberculosis y combatir la enfermedad de manera efectiva.

Área de la Ciencia:

Enfermedades infecciosas Enfermedades infecciosas.
Desarrollo de Drogas Desarrollo de Drogas.
Salud Pública La salud pública.

Sus antecedentes:

Los medicamentos actuales para la tuberculosis (TB) se enfrentan a desafíos por la resistencia inherente y las cepas emergentes resistentes a los medicamentos.
A pesar de los avances, la cartera mundial de productos terapéuticos para la tuberculosis es inadecuada para satisfacer las demandas de tratamiento.

Objetivo del estudio:

Para poner de relieve la insuficiencia de la tuberculosis actual de la tuberculosis de la droga de la tuberculosis.
Identificar los principales desafíos y áreas de mejora en el desarrollo de medicamentos para la tuberculosis.

Principales métodos:

Revisión de la reciente línea de desarrollo clínico de compuestos para la tuberculosis.
Análisis de los desafíos en el desarrollo de nuevos regímenes de medicamentos antituberculosos.

Principales resultados:

Diez compuestos entraron en desarrollo clínico en la última década, con seis específicamente para la TB.
Persisten importantes necesidades no cubiertas debido al insuficiente desarrollo de fármacos y las brechas en la cartera.

Conclusiones:

Los esfuerzos sostenibles, el aumento de la financiación y la acción colaborativa son esenciales para fortalecer el suministro de medicamentos para la tuberculosis.
Abordar los desafíos en nuevas combinaciones de medicamentos, diseños de ensayos, estudios pediátricos y pautas regulatorias es fundamental para la eliminación de la TB para 2050.

Más Videos Relacionados

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Videos de Conceptos Relacionados

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: